PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials. (2023). Biomedical Research and Therapy, 10(12), 6090-6102. https://doi.org/10.15419/bmrat.v10i12.851